Cefprozil
| Systematic (IUPAC) name | |
|---|---|
| 7-[2-amino-2-(4-hydroxyphenyl)-acetyl]amino-8-oxo-3-prop-1-enyl-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid | |
| Clinical data | |
| Trade names | Cefzil |
| AHFS/Drugs.com | monograph |
| MedlinePlus | a698022 |
| Licence data | US FDA:link |
| Pregnancy cat. | B (US) |
| Legal status | ℞-only (US) |
| Routes | Oral |
| Pharmacokinetic data | |
| Bioavailability | 95% |
| Protein binding | 36% |
| Half-life | 1.3 hours |
| Identifiers | |
| CAS number | 92665-29-7 |
| ATC code | J01DC10 |
| PubChem | CID 9887643 |
| DrugBank | DB01150 |
| ChemSpider | 8063315 |
| UNII | 1M698F4H4E |
| KEGG | D07651 |
| ChEBI | CHEBI:3506 |
| ChEMBL | CHEMBL1742 |
| Chemical data | |
| Formula | C18H19N3O5S |
| Mol. mass | 389.427 g/mol |
|
|
|
|
| |
|
Cefprozil, sometimes spelled cefproxil and marketed under the trade name Cefzil, is a second-generation cephalosporin type antibiotic. In Europe it is marketed using the trade names Procef and Cronocef.[citation needed] It can be used to treat bronchitis, ear infections, skin infections, and other bacterial infections.[citation needed] It comes as a tablet and as a liquid suspension.
Although there is a widely quoted cross-allergy risk of 10% between cephalosporins and penicillin, an article in the Journal of Family Practice[1] has shown no increased risk for cross-allergy for cefprozil and several other second-generation or later cephalosporins.
References [edit]
- ^ Pichichero, ME (February 2006). "Cephalosporins can be prescribed safely for penicillin-allergic patients". J Fam Pract 55 (2): 106–12. PMID 16451776.
External links [edit]
- Cefprozil MedlinePlus Drug Information
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| This systemic antibacterial-related article is a stub. You can help Wikipedia by expanding it. |